Raymond James Financial Services Advisors, Inc. Vbi Vaccines Inc Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	SELL	$0.29 - $0.64 $6,375 - $14,069	-21,984 Reduced 18.25%	98,453 $29,000
Q4 2022 Feb 08, 2023	SELL	$0.38 - $22.5 $1,781 - $105,457	-4,687 Reduced 3.75%	120,437 $46,000
Q3 2022 Oct 25, 2022	SELL	$0.73 - $23.4 $36,256 - $1.16 Million	-49,667 Reduced 28.42%	125,124 $88,000
Q2 2022 Aug 12, 2022	SELL	$0.66 - $1.81 $60,955 - $167,166	-92,357 Reduced 34.57%	174,791 $141,000
Q1 2022 May 11, 2022	BUY	$1.27 - $2.47 $27,415 - $53,319	21,587 Added 8.79%	267,148 $443,000
Q4 2021 Feb 08, 2022	BUY	$2.21 - $3.22 $51,022 - $74,340	23,087 Added 10.38%	245,561 $575,000
Q3 2021 Nov 02, 2021	BUY	$2.8 - $3.72 $243,543 - $323,565	86,980 Added 64.19%	222,474 $692,000
Q2 2021 Aug 11, 2021	BUY	$2.61 - $4.17 $21,764 - $34,773	8,339 Added 6.56%	135,494 $454,000
Q1 2021 May 14, 2021	BUY	$2.91 - $4.32 $161,676 - $240,014	55,559 Added 77.6%	127,155 $395,000
Q4 2020 Feb 12, 2021	SELL	$2.15 - $3.5 $128,752 - $209,597	-59,885 Reduced 45.55%	71,596 $197,000
Q3 2020 Nov 04, 2020	BUY	$2.77 - $6.17 $330,978 - $737,234	119,487 Added 996.22%	131,481 $376,000
Q2 2020 Jul 17, 2020	SELL	$0.87 - $3.13 $37,415 - $134,608	-43,006 Reduced 78.19%	11,994 $37,000
Q4 2019 Feb 12, 2020	BUY	$0.48 - $1.38 $26,400 - $75,900	55,000 New	55,000 $76,000

Others Institutions Holding VBIV

# of Institutions

Shares Held

688K

Call Options Held

Put Options Held

Frontier Wealth Management LLC Kansas City, MO

602K
Shares

$12,036
0.01% of portfolio
ETF Managers Group, LLC Summit, NJ

85.7K
Shares

$1,714
0.0% of portfolio

View Full List

About VBI Vaccines Inc

Ticker VBIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 258,256,992
Market Cap $5.17M
Description
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The...

More about VBIV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account